- Home
- OTLY vs NGEN Comparison
OTLY vs NGEN Comparison
Compare OTLY & NGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OTLY | NGEN |
|---|---|---|
| Founded | 1994 | 2017 |
| Country | Sweden | Canada |
| Employees | N/A | N/A |
| Industry | Packaged Foods | |
| Sector | Consumer Staples | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 394.1M | 317.6M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | OTLY | NGEN |
|---|---|---|
| Price | $9.91 | $3.91 |
| Analyst Decision | Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $15.50 | N/A |
| AVG Volume (30 Days) | 49.4K | ★ 98.1K |
| Earning Date | 04-29-2026 | 04-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $7.91 | N/A |
| Revenue Next Year | $5.50 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.35 | $3.55 |
| 52 Week High | $18.84 | $5.93 |
Technical Indicators
Market Signals| Indicator | OTLY | NGEN |
|---|---|---|
| Relative Strength Index (RSI) | 38.05 | 44.52 |
| Support Level | N/A | $3.69 |
| Resistance Level | $12.58 | $4.10 |
| Average True Range (ATR) | 0.53 | 0.24 |
| MACD | -0.10 | 0.03 |
| Stochastic Oscillator | 13.55 | 50.31 |
Price Performance
Historical ComparisonAbout OTLY Oatly Group AB
Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, and Icecreams, among others. It caters to Sweden, Germany, the United Kingdom, Netherlands, North America, Finland, and Other markets. The company generates revenue from the EMEA, Americas, and Asia regions, with the majority of revenue generated from the EMEA region.
About NGEN NervGen Pharma Corp. Common stock
NervGen Pharma Corp is a clinical-stage biotech company. The company's principal business activity is the discovery, development, and commercialization of pharmaceutical treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. The company's initial target indication is spinal cord injury. The company's pipeline products include NVG-291 and NVG-300.